Evidence map›Paper›PMID 39850813›Full record

ArticleFrontiers in oncology2024

Long term outcomes associated with the use of perioperative systemic chemotherapy on low grade appendiceal mucinous neoplasms with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Samantha M Ruff, Gyulnara Kasumova, Manoj Palavalli, Oliver S Eng, Laura Lambert, Callisia Clarke, Sameer Patel, Jula Veerapong, Keith Fournier, Daniel Abbott and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Samantha M RuffDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center/James Comprehensive Cancer Center, Columbus, OH, United States.
Gyulnara KasumovaDivision of Surgical Oncology, Department of Surgery, Central Maine Medical Center, Lewiston, ME, United States.
Manoj PalavalliDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center/James Comprehensive Cancer Center, Columbus, OH, United States.
Oliver S EngDepartment of Surgical Oncology, University of California Irvine Medical Center, Irvine, CA, United States.
Laura LambertDepartment of Surgical Oncology, University of Utah, Salt Lake City, UT, United States.
Callisia ClarkeDepartment of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Sameer PatelDepartment of Surgical Oncology, University of Cincinnati, Cincinnati, OH, United States.
Jula VeerapongDepartment of Surgical Oncology, University of California San Diego, San Diego, CA, United States.
Keith FournierDepartment of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, United States.
Daniel AbbottDepartment of Surgical Oncology, University of Wisconsin Medical Center, Madison, WI, United States.
Charles StaleyDepartment of Surgical Oncology, Emory University Hospital, Atlanta, GA, United States.
Travis GrotzDepartment of Surgery, Mayo Clinic, Rochester, MN, United States.
Fabian JohnstonDepartment of Surgical Oncology, The Johns Hopkins University, Baltimore, MD, United States.
Mustafa RaoofDepartment of Surgical Oncology, City of Hope Cancer Center, Duarte, CA, United States.
Sean DineenDepartment of Surgical Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Jordan M CloydDepartment of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center/James Comprehensive Cancer Center, Columbus, OH, United States.
Alex C KimDepartment of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Low grade appendiceal mucinous neoplasms (LAMN) are indolent tumors that lack invasive potential but may present as pseudomyxoma peritonei. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves both overall and recurrence free survival. While systemic chemotherapy is generally considered ineffective for LAMN, little literature is available to support this notion. We evaluated outcomes for individuals with LAMN who did and did not receive systemic chemotherapy in combination with CRS+HIPEC. Methods: A multicenter retrospective cohort study was performed using the US HIPEC Collaborative that included patients with LAMN who underwent CRS+HIPEC. The overall survival (OS) and recurrence-free survival (RFS) of patients who did and did not receive systemic chemotherapy were compared. Survival and variables associated with survival were evaluated with the Kaplan-Meier analysis and cox regression, respectively. Results: Among the 529 included patients with LAMN, 63 (11.9%) received systemic chemotherapy and CRS+HIPEC, while 466 (88.1%) were treated with only CRS+HIPEC. Patients selected for systemic chemotherapy had a higher burden of disease (mean peritoneal cancer index: 18.8 +/- 8.6 versus 14.3 +/- 8.8, p<0.001). Patients who were not treated with chemotherapy had better mean OS and RFS (OS: 104.3 +/- 6.2 months, RFS: 84.9 +/- 6.6 months) compared to those who underwent systemic chemotherapy (OS: 70.2 +/- 6.8 months, RFS: 38 +/- 5.9 months, p<0.001). Increasing pre-operative CEA level (HR 1.012, p<0.001), higher completeness of cytoreduction score (reference CCR 0, CCR2 HR 34.175, p=0.001 and CCR3 HR 52.041, p=0.001), and treatment with systemic chemotherapy (HR 4.196, p=0.045) were associated with worse OS. Conclusions: In this multicenter retrospective study, the receipt of perioperative chemotherapy was associated with worse long-term outcomes among patients with LAMN undergoing CRS-HIPEC. Systemic chemotherapy may lead to patient deconditioning and contribute to worse long-term outcomes. It should not be recommended outside of a clinical trial.

Indexed as

chemotherapycytoreductive surgeryHIPECLAMNlow grade appendiceal mucinous neoplasm

Identifiers

PMID39850813
PMCPMC11754268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.